CAS: 1004757-96-3
Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
---|---|---|---|---|
N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide REF: 3D-EQB75796CAS: 1004757-96-3 | Min. 95% | A consultar | Ter 21 Jan 25 | |
BMS-741672 REF: TM-T71640CAS: 1004757-96-3 | - - - | 2.890,00 €~5.288,00 € | Seg 10 Mar 25 |
N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide
CAS:1004757-96-3
N-[5-[Methyl(propan-2-yl)amino]-2-[2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide (NAPQI) is a new drug that is being developed for the treatment of autoimmune …
Fórmula:
C25H33F3N6O2
Pureza:
Min. 95%
Peso molecular:
506.6 g/mol
Ref: 3D-EQB75796
100mg | A consultar | ||
250mg | A consultar |
Entrega estimada em Estados Unidos, Terça-feira 21 de Janeiro de 2025
BMS-741672
CAS:1004757-96-3
BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain.
Fórmula:
C25H33F3N6O2
Cor e Forma:
Liquid
Peso molecular:
506.56
Ref: TM-T71640
25mg | 2.890,00 € | ||
50mg | 3.811,00 € | ||
100mg | 5.288,00 € |
Entrega estimada em Estados Unidos, Segunda-feira 10 de Março de 2025